$JNJ RESULTS: 🔸 Q1, - ADJ EPS $2.77 vs. $2.71 y/y, EST $2.60 🔸 Sales $21.89B, +2.4% y/y, EST $21.58B 🔸 MedTech sales $8.02B, +2.5% y/y, EST $8.19B 🔸 Imbruvica revenue $709M, -9.6% y/y, EST $680.3M 🔸 Invega Sustenna revenue $903M, -14% y/y, EST $1.06B 🔸 Darzalex revenue $3.24B, +20% y/y, EST $3.1B 🔸 Erleada revenue $771M, +12% y/y, EST $818.5M 🔸 Tremfya revenue $956M, +18% y/y, EST $930.2M 🔸 Remicade revenue $467M, +7.6% y/y, EST $364.1M 🔸 Stelara revenue $1.63B, -34% y/y, EST $1.61B 🔸 Zytiga revenue $125M, -31% y/y, EST $124.8M 🔸 Xarelto revenue $690M, +33% y/y, EST $521.1M 🔸 Simponi rev. $659M, +19% y/y, EST $509.7M 🔸 R&D expenses $3.23B, EST $3.61B F/Y GUIDANCE 🔸 Sees sales $91B to $91.8B, saw $89.2B to $90B 🔸 Sees ADJ operating EPS $10.50 to $10.70, saw $10.75 to $10.95 🔸 Still sees ADJ EPS $10.50 to $10.70